Sign In

Michael Goldberg

CEO at STIMIT

Michael Goldberg is the CEO of STIMIT, a company that has developed a technology platform focusing on extended localized release of cancer immunotherapy during surgical tumor resection for enhanced efficacy and safety.

With a background in academia, Michael has published in prestigious journals like Cell, Nature, Science, Nature Biotechnology, and Science Translational Medicine.

His dedication to clinical translation led him to prioritize the deployment of immunotherapy in the context of cancer surgery, believing it has the potential to become the standard of care.

He holds a PhD in Biological Chemistry from the Massachusetts Institute of Technology, an MPhil in BioScience Enterprise from the University of Cambridge, and a Bachelor's Degree in Biological Chemistry from the University of Toronto.

Prior to his role at STIMIT, Michael held positions as an Assistant Professor at the Dana-Farber Cancer Institute and Harvard Medical School, in addition to being a Post-doctoral fellow at MIT.

Michael Goldberg
Add to my network

Location

Cambridge, Massachusetts